e7389

Eribulin (B1939) is a nonpaclitaxel microtubule kinetic inhibitor with anticancer activity that inhibits polymerization of microtubule protein subunits by preventing lengthening and shortening of microtubules during cell division.Eribulin is used in the study of metastatic breast cancer and solid tumors.

Eribulin mesylate (E7389 mesylate) belongs to natural product derivatives and is a microtubule-targeted anticancer agent, functioning as a microtubule dynamics inhibitor that suppresses tubulin polymerization through tubulin binding, with cell permeability. This drug is used for the treatment of metastatic breast cancer.

Fmoc-PEG6-VCP-Eribulin is a derivative of Eribulin. Eribulin (E7389) is an anticancer agent targeting microtubules (microtubule) and is utilized in the study of metastatic breast cancer. It inhibits cancer cell proliferation by binding to tubulin and microtubules.